RE: Numbers Today14 May 2020 18:20
Rns snippet
Although the Group had cash and cash equivalents of $912 million (net cash of $674 million) as of March 31, 2020 and COVID-19 has not had a material financial impact on the Group to date, the Group has observed a meaningful decline in patient enrollments for both SUBLOCADE and PERSERIS injections. The pandemic has likely resulted in fewer patient visits to healthcare provider offices for non-COVID-19 reasons, as patients become unable or unwilling to make visits due to overburdened healthcare systems, safety concerns, quarantines or other travel restrictions. In addition, the Group's commercial organization is unable to engage in-person with healthcare professionals (HCPs) and Organized Health Systems (OHS) - an important element of the Group's growth strategy - while remote working requirements are in place. A potential significant decline in patient enrollments and the inability to effectively engage with HCPs and OHS could have a negative impact on the Group's financial results in future periods.